Avalo Therapeutics (AVTX) Free Cash Flow (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Free Cash Flow data on file, last reported at -$17.7 million in Q1 2026.

• Quarterly Free Cash Flow fell 87.16% year-over-year to -$17.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59.7 million (down 14.21% YoY) and the FY2025 annual result came in at -$51.5 million, down 4.98% from the prior year.
• Free Cash Flow fell to -$17.7 million in Q1 2026, from -$14.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $5.8 million in Q3 2022 to a low of -$17.7 million in Q1 2026.
• A 5-year average of -$10.3 million and a median of -$11.3 million in 2025 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow surged 131.65% — and 2024, when it tumbled 443.89%.
• Tracing AVTX's Free Cash Flow over 5 years: stood at -$4.0 million in 2022, then soared by 31.45% to -$2.8 million in 2023, then plunged by 443.89% to -$15.0 million in 2024, then climbed by 5.03% to -$14.3 million in 2025, then fell by 23.88% to -$17.7 million in 2026.
• The last three Free Cash Flow figures came in at -$17.7 million (Q1 2026), -$14.3 million (Q4 2025), and -$16.4 million (Q3 2025), per Business Quant data.